| Authors: |
Bellmunt J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. joaquim.bellmunt@gmail.com.; Htal Del Mar Research Institute-IMIM, Barcelona, Spain. joaquim.bellmunt@gmail.com., Lalani AA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Juravinski Cancer Centre, McMaster University, Hamilton, Canada., Jacobus S; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Wankowicz SA; The Eli and Edythe L. Broad Institute of Harvard and MIT, Cambridge, MA, USA., Polacek L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Takeda DY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Harshman LC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wagle N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Eli and Edythe L. Broad Institute of Harvard and MIT, Cambridge, MA, USA., Moreno I; Fundación Jiménez Díaz University Hospital, Madrid, Spain., Lundgren K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bossé D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Eli and Edythe L. Broad Institute of Harvard and MIT, Cambridge, MA, USA., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Rosenberg JE; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. |
